抽象的
背景:Currently there is major lack of knowledge on the diagnostic and therapeutic management of patients with Idiopathic Pulmonary Fibrosis (IPF) and lung cancer (LC).
Objectives:1) To identify variations in diagnostic and management strategies across different institutions. 2) To provide rationale for a consensus statement on this issue.
Results:This was a joint-survey by ERS Assemblies 8, 11 ad 12. The survey consisted of 25 questions. 494 physicians from 68 different countries and 5 continents responded to the survey. 94% of participants were pulmonologists and 1.8% thoracic surgeons and 1.9% oncologists. 67% and 21.6% were from University and non-University hospitals, respectively and 26.3% were treating > 50 patients with IPF per year. 97.7% involved MDT approaches on diagnosis and management. Regular low-dose HRCT scan was used by 49.5% of the respondents to screen for LC in IPF. PET scan and EBUS bronchoscopy was performed by 60% and 88% to diagnose nodular lesions with mediastinal lymphadenopathy in patients with advanced and mild IPF, respectively. 83% of respondents continue anti-fibrotics following LC diagnosis; safety precautions during surgical interventions including low-tidal volume were applied by 67%. Stereotactic radiotherapy was used to treat patients with advanced IPF (DLCO<35%) and otherwise operable NSCLC in 54% of respondents and doublet platinum regimens and immunotherapy for metastatic disease in 25% and 31.9%, respectively. Almost all participants (93%) replied that a consensus statement for the management of these patients is necessary.
结论:Considering the heterogeneous practices in LC-IPF became evident, most respondents called for a consensus statement.
脚注
引用本文为:2019年欧洲呼吸杂志;54:补充。63,OA249。
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available atwww.ers-education.org(ERS member access only).
- 复制right ©the authors 2019